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Results: In Cox.proportional hazard anaty.~es, low peak VO~ (p ~ O0014), 
tow LVEF (p ~ 0,0004), and high UA (p . 00001, RR 1007 [95% CI 
1.005--1.010D. but not age (p ~ 0,09) predicwd poor prognosis, Patients with 
ovont.fre~ survlvl~l had a mean UA o! 451 :t: 110 mol,1 (patents with event 
591 ~. 166 reel,'1, p ~- 00001), UA levels nbovo median ( ~,46B mol~,, RR 423 
(95%CI 2,0-=9,2]), in the higbe~t t~niie (;_.560 mot/I, RR 6,75 (3,3-14.0)), and 
in the high,st q+~adilo (~590 mol, l, RR 7+L~ [3+6-~4,7}, s~l p ~ 00001) w~re 
strong progno~ic pmd~oe~, mo'ependently of ago, peak V0~, LVEF and 
diumt¢ ~o~, LVEF ~ 25% (RR 3+'-~ [1,5-7,!], p ; 0,0014) and p#ak VO~ 
< 14 (RR 202 |1,03-.4=0], p < 0,05) were I~s_ ~tfong pro(~o~tt¢ markers. 
Ol the 7 patmnls Ihat h~l UA ~ 5g0, LVEF < 25, an~ a peak VO~ +: 14 
O,e, 3 RF) non~ sun, Wed ~482 days (16 rno~th~), ~ ll~f~eth ~gfvIva! ~,t 
~tm.m mm 2 RF (37% lOS% cl ~l) ,  I nF (7~ l~-g1%l! arm no 
RF (g~- [8.3-100%]) w~s_ I~ftef, 
~ :  High UA Ira/el8 am a ~1~ ~ ol +repaired p(OgnoSiS In 
CHF patients, additive to 01her esta~blishe(I risk factor~. 
1~70~ A©Ute l~f!phefa!  Edema in  I~t!ent= With Chfon~ 
" ; .... H4~rl Fa!!um Is Asso~iall~d With Endolaxem!a 
a~ Immune Activation 
J N~uer  t , M. Kemp ~ ,M Doming~ez ~ , M. Ralx:hhaus ~ ,
P PooJe-Wilson ~ , A, Coats ~ , S- An kerr. 'Royal Bmmpton Hosprtal and 
Naemna~ Heart & Lung Ins/~ruee. ~ UK; ZHeart Soence Center, 
Ham#ekl Hos~tal, UK 
Background: It has been re~ogn~,ed that patients wrth chr0n,c heart failure 
(CHF) exhibd immune actlvat,.on. We have recently hypothes~ed that im- 
mune act~tion may be tnd~-ed by bacterial translocat~0n from the intestine 
tO the bk:~od stream due to venous congeslion and altered gut pon'neability 
Thus, we stucbed palmers at the Ormet ot severe peripheral edema postulating 
that these l~ l~b l  were ff~ost fike~y to h3w~ bowel wall edema. 
Methods: Patienls with CHF (n = 39) and healthy contre~s ( n = 8) under- 
e~nt rou~ physical examinabon, ECG. beood tes~ng, an~ chest x-ray, at 
the beginning of the study. So(teen patients were diagnosed with severn pe- 
npheral edema (CHF-edema) ~tood samples tot endatomn measurements 
(LAL test) were colfo~ed in endofo,,on flee lubes. In a subgroup of pallents (n 
= 14) and conhots (n = 4) CD3. CD4, COS. CD25 were measured by FACS 
analysis. 
Resuff~: Endotcxm levels were lower in conlm~s (0.391 _+ 0096 EU~ml) 
than m patrents wittmut edema (0.436 = 0057 EU,,ml; p = n.s.) and CHF- 
edema (0.799 ± 0.119 EU/ml; control and CHF w3 CHF-edema, both p < 
0.01) W'nile no slgni'hcent dlfferenoes were detected for CD3,CD4, and CD8, 
results for CD3;25 and CD8/25 mCrrered those of endetomn revels, wdh high- 
est levels in CHF-edema (CD3~5: controls, 10.25 +- 0 629 vs CHF-eo'ema, 
32 6?" ± 12 68°,0 p ~ 0.02; CD8/25: controls, 45 = 0.29 vs CHF-edema, 
1867 ¢ 648%, p < 0.02), which is suggestive of acute immune act~ve- 
t~on 
Conclusion: These findings suggest a possible role for endoTomn-mduced 
immune acttvabon in CHF pabents with recent onset ot penphoral edema. 
I i070-33 1 The Association of High Dose Diuretics W'dh 
Prognosis in Heart Failure 
K.J. Haq3i. 1". Turgut, H.W. Thompson ~ , M Shah. F. Smart, H Venture. 
Ochsner &¢ed~cal lns~turions. USA: ~ LSU &fedtcal Center. New Orleans. 
Louisiana. USA 
Background: Diuretic agents are commonly employed in the management 
ot patients (pts) with heart failure (HF). We sought to assess the relation 
between the use of high doses of diurel~ and long-term outcome in HF 
Methods: 111 pts (63% men; age 69 yrs) w~th moderate to severe LV 
dysfunction (EF ~ 30%) were followed for 9.8 ± 7.6 months following a 
hospitalization for HF. We classified pts into those who were consistently 
treated with high doses o! diuretics (furosem~de ~80 mg/d or equivalent 
amount of other diuretic) for outpatient maintenance therapy (Gr I: n = 47) 
and those who were not (Gr It: n = 64). We compared the occurrenCe o1" poor 
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outcomo, dofin~:l as ~,[)ath (n = 44) or uegent bear transptamat~ot~ (n ~ 0t L 
over the follow-up peeod between the two group~ 
Results The groups were similar in a~, gen0et, race. anO ,nc,len~e 
O! Ilypertension, CAD, dtabefa~, and atrial flpnllet~on Gr I pls nod a h,,g~ef 
~n¢¢l~nCo ot RV dystunction (65 vs 40%) and were more likely tO ~ve NYHA 
class Ill 0r IV (53% v~ 33%', p < 0,05 fOr 8!l). Poet ouaco~ w~l ~t  rf~r~ 
fm~l~emtly in Gr ! (51 va ~B%: g = 0,01); ~unm/al ar, a~ (grt~pt~) S ~  
e~rtlor oc~u~n¢~ ot poor o ~  in Gr ! (p = 0,01L In ~ n m  emah~, 
I~gh o~o~e diuret¢ use wa~ mdal~mt ly  ~ooated  w;th poor outcome 
(odds mite 3,9: 95% C! I,tl-9,6), 
Conct~s~n~: In pt~ w~lh HF, the ~ f~r 0utl~be~ lhersl~ w~ h~ 
oos~.ret=~ is ~ strong market of I,~ot ~erm o~com~, 
11070,34 i Ihc,mClUClbtllty of  th~ NMf lumic  IN~ptiCkm for t im 
................. Oetllction o f  Vemtrlcutlr Oy l funct ion - 
ComParttmn to  the C I In~l  Evaluatiot! ilI Different 
Populat ions 
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LISA 
The use of Blain |BNP), C-temmnat Areal (C-ANP), ~ Noten'nma| Area| 
(N+ANP) natnuretl¢ peplicles to Oetecl LV dysfunction (LVD) has been prO- 
posed, To ~ n e  d these papt~es pedorm Conm~ in OU1-~s  
(pts) at risk for LV dysfunction as compared to clincal predclo,m o! LVD, we 
analyzed c!in~l parameters, BNR C.ANP aed N-ANP m 304 out.eta (Grp 
A) refan'ed for echo to, check EF because ot symploms el of nsk factors tot 
LVD A timbal ecom (+ Or - )  using ~ I~story, CXR and ECG pmdlc~ve 
ot LVD was devefo l~ The ~ l  scorn and peplldas were then 
prospectively m 162 pts (Gin B). Recewer operating characteristic (ROC) 
analysis was pewformed. For deteel~n of an EF < 35%. the areas under Ihe 
ROC curve (&UC) for Grp A were: BNP : 0.88, N-ANP : 0.67', C-ANP : 
0.82 and for Grp B were: BNP = 0.99, N-ANP = 079', CANP = 0.96 (' = p 
0.02 vs. BNP). An abrmmla! BNP (> or : 37 pg/mt) was 87% sensdive 
6t% speofic m Grp A and 100% imnsdJva and 62% specific in Grp B. A + 
clinmat scorn was 100%, sensdrve and 62"/. speofic for delectien of an EF < 
35% in Grp A and 63% set~'itrve and 54% spa~f¢ in GW B. In cenctusmn, 
the pred~'~e value o! BNP or C-ANP rs repreduC~ie am] was equivalent 
to that defivecl from a complete c~ca l  evaluallon mcluc~ng physioan ve~t, 
CXFI and ECG. These data s ~  the use of BNP or C-ANP to screen for 
LVD 
~ Plasma BNP Concentration Is the Most Sensitive 
Marker for Management of Chronic Congestive 
Heart Failure 
t Hamenaka, Y. Satto, t. Masuda, Y Mtysmoto, M Harada. K Kuwahara, 
E Ogawa. N. Kajiyama Kazuwa Nakao Kyoto Unwersr~. Kyoto, Japan 
Background: Echec~diography is the ge~den standard for evaluating the 
effect el treatments m patients w,;th chronic co~gaslwe heart failure (CHFL 
but sometimes ~ changes are too small to make oblecttve veluabon. Brain 
natnuretic peplide (BNP) Is an only humors! factor released from ventncutar 
cardiomyocyles and its plsma level is augmented in accordance with seventy 
of CHF In this stu~ we evaluated wbelher BNP COUld be a ser~ItiVe marker 
for the management ot CHF. 
Afethods: 10 patients with acute decompensation of CHF were treated 
with diuretTcs. ACE inhibitors and b-blockem. 
Resuffs: The plasma BNP level was significantly decreased after 1 week 
treatment, although electrons fraction (EF) was not changed at this lima 
(fig) EF had subsequently n-nproved 1 month tier. Left ventncular diastolic 
dimension had no sTgnifmant change dunng 1.year follow up. ANP had 
tendency to decrease after the 1-week treatment. 
BNP(pg/ml) EFt%) 
1600 . . . . . . . . . .  • 60_ 
8O0 S 
0 lw  ~N lm 3"n 3m 4rn 8m ly 
• <0.05 ,  °*<0.01  vS day 0 
Conclusion: The change in the plasma BNP concentration in patients with 
CHF precedes the ~mprevement of EL=. and so the plasma BNP concentration 
is one of the mo'=t sensitive markers of cardiac function in patients with CHF. 
